The new Svar Life Science iLite® Metabolic Panel accelerates metabolic drug development with functional GLP-1, GIP, FGF-21, and insulin signaling data.
Metabolic drug development is advancing rapidly, moving beyond single-target therapies and towards more complex dual- and triple-agonist approaches. To develop the next generation of metabolic therapeutics, researchers need functional data that can help evaluate biological activity across multiple pathways relevant to obesity, diabetes, and related metabolic diseases.
To support these evolving needs, Svar Life Science launches the iLite® Metabolic Panel, a suite of assay ready, cell-based reporter gene assays designed for functional characterization and potency assessment of candidates targeting GLP-1, GIP, FGF-21, and insulin signaling.
The panel includes:
Thanks to the shared proprietary assay ready reporter gene assay platform, the iLite® Metabolic Panel enables direct comparison of activity across individual metabolic pathways while maintaining consistency in assay design, performance, and workflow. This allows to evaluate targets individually or in combination to support more complex single-, dual-, and triple-agonist programs involving peptide therapeutics, biologics, and emerging metabolic drug candidates.
To develop the next generation of dual- and triple-agonist therapies, researchers need more than receptor binding data. They need functional insights that reflect biological activity and mechanism of action to truly understand how a candidate functions at each biological target.
This is where cell-based reporter assays can play an essential role. Functional cell-based reporter assays unlock insights into the mechanism of action of drug candidates by translating pathway activation into measurable functional readouts. This gives researchers a biologically relevant way to connect molecular design with cellular activity and generate data that can support development decisions.
Rather than looking at isolated molecular interactions, cell-based functional assays help translate complex signaling events into quantitative and reproducible data. This can provide valuable insight during candidate selection, mechanism-of-action investigations, potency assessments, and comparability studies.
The iLite® Metabolic Panel has been developed with all these needs in mind. Covering key pathways involved in metabolic regulation, including GLP-1, GIP, FGF-21, and Insulin signaling, the panel enables researchers to investigate target-specific activity using reporter gene technology designed to reflect cellular responses.
For developers, the value lies in speed, relevance, and flexibility: functional readouts that reflect pathway activation, assay ready models that simplify setup, and a modular panel that can be tailored to the questions being asked in each program. High assay sensitivity and broad dynamic range help support robust quantification of biological responses, enabling confident assessment across a wide range of activity levels.
All iLite® assay ready cells are supplied in a thaw-and-use format, helping reduce preparation time and enabling assays to be completed in under one day. This streamlined workflow allows researchers to generate biologically relevant data faster and make informed development decisions with greater confidence.
Whether developing a GLP-1 agonist, a dual incretin therapy, or a next-generation metabolic therapeutic, researchers can tailor the iLite® Metabolic Panel to their program needs and accelerate progress from discovery to development.
Working on a single-target therapy or a multi-agonist candidate? Contact your Bio-Connect account manager or our technical support team to discuss the Svar Life Science iLite® Metabolic Panel, request product documentation, or check availability. Our team is happy to help you select the iLite® assays that best match your program.
How can the functional activity of liraglutide, tirzepatide, and retatrutide be assessed across GLP-1 and GIP pathways? The Svar Life Science flyer presents dose-response curves, relative potency data, and linearity results for the GLP-1 and GIP assays. It also explains how receptor activation translates into a measurable signal and outlines the workflow from thawing to readout within the same working day.
View the document for more information on the workflow and assay performance data.
iLite Cell-based Reporter Gene Assays | RUO ELISA kits | Complement | Calprotectin | Gene Therapy | Calpro AS | Wieslab AB
We gladly support you by keeping you updated on our latest products and developments
